Rubin Steven D.'s Insider Trades & SAST Disclosures
Rubin Steven D.'s most recent trade in Eloxx Pharmaceuticals Inc was a trade of 3,750 Common Stock done . Disclosure was reported to the exchange on Jan. 24, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Rubin Steven D..To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Eloxx Pharmaceuticals Inc | Steven D. Rubin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jan 2025 | 3,750 | 15,750 (0%) | 0% | 0 | Common Stock | |
| Eloxx Pharmaceuticals Inc | Steven D. Rubin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jan 2025 | 3,750 | 3,750 | - | - | Restricted Stock Units | |
| Red Violet Inc | Steven D. Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Nov 2024 | 8,000 | 151,138 (1%) | 0% | - | Common Stock | |
| Eloxx Pharmaceuticals Inc | D. Steven Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Oct 2024 | 12,000 | 12,000 (0%) | 0% | 0 | Common Stock | |
| Cocrystal Pharma Inc | Steven D. Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Oct 2024 | 18,957 | 2,660,242 (5%) | 0% | - | Common Stock | |
| Opko Health Inc | Steven D. Rubin | Director, Executive VP-Administration | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2024 | 437,500 | 6,625,232 (0%) | 0% | 0 | Common Stock | |
| Niagen Bioscience Inc. | Steven D. Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Eloxx Pharmaceuticals Inc | D. Rubin Steven | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 7,500 | 7,500 | - | - | Restricted Stock Units | |
| Opko Health Inc | D. Steven Rubin | Director, Executive VP-Administration | Purchase of securities on an exchange or from another person at price $ 0.87 per share. | 05 Jan 2024 | 10,000 | 6,187,732 (0%) | 0% | 0.9 | 8,669 | Common Stock |
| Red Violet Inc | Rubin Steven D. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Nov 2023 | 10,800 | 143,138 (1%) | 0% | - | Common Stock | |
| Cocrystal Pharma Inc | Steven D. Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2023 | 17,233 | 17,233 | - | - | Stock Options (Right to Buy) | |
| Niagen Bioscience Inc. | Steven D. Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Niagen Bioscience Inc. | Steven D. Rubin | Director | Purchase of securities on an exchange or from another person at price $ 1.46 per share. | 25 May 2023 | 7,000 | 7,000 (0%) | 0% | 1.5 | 10,220 | Common Stock |
| Opko Health Inc | Steven D. Rubin | Director, Executive VP-Administration | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 700,000 | 700,000 | - | - | Stock Option (Right to Buy) | |
| Eloxx Pharmaceuticals Inc | Steven D. Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2023 | 2,859 | 2,859 | - | - | Stock Options (Right to Buy) | |
| Red Violet Inc | Steven D. Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Oct 2022 | 10,800 | 132,338 (1%) | 0% | - | Common Stock | |
| Cocrystal Pharma Inc | Steven D. Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jul 2022 | 188,000 | 188,000 | - | - | Stock Options (Right to Buy) | |
| Niagen Bioscience Inc. | Steven D. Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Eloxx Pharmaceuticals Inc | Steven D. Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 20,000 | 20,000 | - | - | Stock Options (Right to Buy) | |
| Red Violet Inc | Steven D. Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Sep 2021 | 8,900 | 121,538 (1%) | 0% | - | Common Stock | |
| Cocrystal Pharma Inc | Steven D. Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jul 2021 | 88,000 | 88,000 | - | - | Stock Options (Right to Buy) | |
| Niagen Bioscience Inc. | Steven D. Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 20,000 | 20,000 | - | - | Stock Options (right to buy) | |
| Eloxx Pharmaceuticals Inc | Steven D. Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2021 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Opko Health Inc | Steven D. Rubin | Director, Executive VP-Administration | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2021 | 350,000 | 350,000 | - | - | Stock Option (Right to Buy) | |
| Red Violet Inc | Steven D. Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2020 | 7,000 | 112,638 (0%) | 0% | - | Common Stock | |
| Opko Health Inc | Steven D. Rubin | Director, Executive VP-Administration | Purchase of securities on an exchange or from another person at price $ 3.99 per share. | 26 Aug 2020 | 5,000 | 6,162,732 (0%) | 0% | 4.0 | 19,950 | Common Stock |
| Opko Health Inc | Steven D. Rubin | Director, Executive VP-Administration | Purchase of securities on an exchange or from another person at price $ 4.01 per share. | 26 Aug 2020 | 2,500 | 6,167,732 (0%) | 0% | 4.0 | 10,025 | Common Stock |
| Opko Health Inc | Steven D. Rubin | Director, Executive VP-Administration | Purchase of securities on an exchange or from another person at price $ 3.99 per share. | 26 Aug 2020 | 2,500 | 6,165,232 (0%) | 0% | 4.0 | 9,968 | Common Stock |
| Cocrystal Pharma Inc | Steven D. Rubin | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2020 | 72,000 | 72,000 | - | - | Stock Options (Right to Buy) | |
| Niagen Bioscience Inc. | Steven D. Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jun 2020 | 20,000 | 20,000 | - | - | Stock Options (right to buy) | |
| Opko Health Inc | Steven D. Rubin | Director, Executive VP-Administration | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2020 | 350,000 | 350,000 | - | - | Stock Option (Right to Buy) | |
| Eloxx Pharmaceuticals Inc | Steven D. Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2020 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges